These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17954424)

  • 1. Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
    Sleilati GG; Leff T; Bonnett JW; Hegele RA
    Endocr Pract; 2007 Oct; 13(6):656-61. PubMed ID: 17954424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy.
    Iwanishi M; Ebihara K; Kusakabe T; Chen W; Ito J; Masuzaki H; Hosoda K; Nakao K
    Metabolism; 2009 Dec; 58(12):1681-7. PubMed ID: 19793595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report.
    Moreau F; Boullu-Sanchis S; Vigouroux C; Lucescu C; Lascols O; Sapin R; Ruimy D; Guerci B; Pinget M; Jeandidier N
    Diabetes Metab; 2007 Nov; 33(5):385-9. PubMed ID: 17936664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report.
    Collet-Gaudillat C; Billon-Bancel A; Beressi JP
    Diabetes Metab; 2009 Apr; 35(2):151-4. PubMed ID: 19249234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative whole-body MRI in familial partial lipodystrophy type 2: changes in adipose tissue distribution coincide with biochemical improvement.
    McLaughlin PD; Ryan J; Hodnett PA; O'Halloran D; Maher MM
    AJR Am J Roentgenol; 2012 Nov; 199(5):W602-6. PubMed ID: 23096204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
    Iizaka T; Kodama E; Mikura K; Iida T; Imai H; Hashizume M; Kigawa Y; Sugisawa C; Tadokoro R; Endo K; Otsuka F; Isoda M; Ebihara K; Ishibashi S; Nagasaka S
    Endocr J; 2023 Jan; 70(1):69-76. PubMed ID: 36171144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report.
    Prasithsirikul W; Bunnag P
    J Med Assoc Thai; 2004 Feb; 87(2):166-72. PubMed ID: 15061300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pharmacogenetic Approach to the Treatment of Patients With
    Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
    Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome.
    Edgeworth A; Treacy MP; Hurst TP
    AIDS Rev; 2013; 15(3):171-80. PubMed ID: 24002201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe acanthosis nigricans in a 17 year-old female with partial lipodystrophic syndrome.
    Valizadeh N; Tehrani MR; Amoli MM; Bandarian F
    J Pediatr Endocrinol Metab; 2008 Nov; 21(11):1027-8. PubMed ID: 19189695
    [No Abstract]   [Full Text] [Related]  

  • 11. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
    Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
    Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions.
    Okada S; Konishi M; Ishii H
    BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26917795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist.
    Banning F; Rottenkolber M; Freibothe I; Seissler J; Lechner A
    Diabet Med; 2017 Dec; 34(12):1792-1794. PubMed ID: 29044799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety.
    Simha V; Rao S; Garg A
    Diabetes Obes Metab; 2008 Dec; 10(12):1275-6. PubMed ID: 19040647
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
    Smith SR; De Jonge L; Volaufova J; Li Y; Xie H; Bray GA
    Metabolism; 2005 Jan; 54(1):24-32. PubMed ID: 15562376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
    Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
    Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
    Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
    Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
    Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
    Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.